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Synthetic peptideStructural changes of proteins are thought to involve speciﬁc protein–peptide interactions, thus we
hypothesize that certain peptides may contribute to the conformational change of prion proteins.
Hence peptide libraries were constructed from partial digests of bovine brain. Using a recently
developed conversion assay method, we have screened peptides responsible for structural conver-
sion. Positive components were identiﬁed of which amino acid sequences were elucidated by top-
down sequencing using mass spectrometry. A database search identiﬁed a peptide derived from syn-
aptophysin. This peptide was chemically synthesized to conﬁrm acceleration of the structural
change of recombinant bovine prion protein.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction mation of rbPrP. The present paper describes the construction of aStructural changes and self-assembly of proteins are thought to in-
volve speciﬁc protein–peptide interactions [1,2], hence proteins desig-
nated as molecular chaperones are known to assist structural
conversionor folding. In contrast to theknowneffectsofb-sheetbreak-
er peptides [3], we suggested a possible reverse phenomenonmay ex-
ist in which certain peptides may induce or enhance putative b-sheet
structures. Understanding the mechanisms of the self-assembly of
peptides/proteins is of paramount importance for the elucidation of
conformational diseases, such as bovine spongiform encephalopa-
thy or human Creutzfeld–Jakob disease, as these will contribute to
the development of therapeutic agents against prion diseases [4].
Recently we have developed a structural conversion assay sys-
tem using designed peptides based on previous NMR spectroscopic
and crystallographic studies with recombinant bovine prion pro-
tein (rbPrP) [5] to investigate the validity of the above hypothesis.
We have shown that the co-existence of certain peptides inﬂu-
enced the kinetic rate of aggregation and the lag-time of ﬁbril for-peptide library from natural bovine brain by partial hydrolysis.
Peptide components that accelerated structural changes of rbPrP
were identiﬁed and further puriﬁed. The amino acid sequences of
these were elucidated by top-down sequencing using matrix-as-
sisted laser desorption/ionization-time-of-ﬂight mass spectrome-
try (MALDI-TOF-MS) followed by MS/MS. These peptides were
then chemically synthesized to conﬁrm their inﬂuence on both
the lag time and rate of structural conversion of rbPrP.
2. Materials and methods
2.1. General
Reagents, except those for peptide synthesis, and solvents were
from Nacalai Tesque, Kyoto, Japan and used as received. The re-
agents for peptide syntheses, such as amino acid derivatives, solid
supports, and coupling reagents were from HiPep Laboratories
(Kyoto, Japan). Water was prepared by a Milli-Q apparatus (Milli-
pore, Tokyo, Japan).
2.2. Construction of brain peptide library
Bovine whole brain was obtained from a local slaughter house
and frozen until homogenized. Freshly frozen bovine brain
Fig. 1. Chromatogram of tryptic digests prepared from bovine brain. Column:
HiPep-Intrada (250  10 i.d. mm); Elution solvents: (A) 0.01 N HCl; (B) acetonitrile
(linear gradient: B 5–60% in 30 min); ﬂow rate: 3 mL/min; 40 C; monitored at
210 nm, Fractionation every 1 min from 4–29 min. Fractions No. 4 (7–8 min) and
No. 12 (15–16 min) showed signiﬁcant effects in the screening assay.
Fig. 2. Re-chromatogram of Fraction No. 4 (upper) and No. 12 (lower) in Fig. 1.
Column: HiPep-Intrada (150  3 i.d. mm); ﬂow rate: 0.4 mL/min; 40 C; monitored
at 210 nm. Upper: Elution solvents: (A) 0.05% TFA; (B) acetonitrile (linear gradient:
B 2–10% in 10 min then 10% in 5 min), Fractionation every 0.5 min. Lower: Elution
solvents: (A) 0.05% TFA, 20% acetonitrile; (B) 0.05% TFA, 25% acetonitrile (linear
gradient: 0–10 min of B then isocratic B. Fractionation every 2 min).
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fuged (10000 rpm for 30 min at 4 C). The resulting viscous precip-
itate (148 g) was suspended in chloroform/methanol (3:1 v/v)
(150 mL) and centrifuged (10000 rpm for 15 min at 4 C). The mid-
dle layer was collected and re-suspended in chloroform (50 mL),
centrifuged as above and the upper layer afforded 44.3 g of wet
material.
This material (10 g) was re-suspended in water (20 mL) centri-
fuged, and the resulted precipitate was washed with 5% NaCl solu-
tion (20 mL). The precipitate was dissolved in 1% NaOH (30 mL),
diluted with water (45 mL) and centrifuged. The supernatant was
neutralized with HCl to pH 6.3 to give precipitate (4.1 g). The
resulting material (0.5 g) was dissolved in 0.02 M NaHCO3
(5.0 mL) and subjected to enzymatic digestion (trypsin, chymotry-
osin or pepsin, 25 mg, respectively). For pepsin digestion 25 mg en-
zyme was used with the above material (0.5 g) in 0.01 M HCl
(5.0 mL).
The digestion was carried out at 37 C for 2, 4, 6, 8, 10 h, respec-
tively. The resulted digests were chromatographed on a semi-pre-
parative column (HiPep-Intrada, 250  10 i.d. mm, HiPep
Laboratories), at 40 C. Positive fractions were further puriﬁed
using an analytical column with the same packing material
(150  3 i.d. mm).
2.3. Screening of libraries by the structural conversion assay
Fluorescence was measured on a spectroﬂuorophotometer RF-
5300PC (Shimadzu) or CytoFluor II (Perseptive Biosystems) with
a 96-well Black Flat Bottom Polystyrene NBS Microplate #3650
(Corning). The time course of rbPrP aggregation in the presence
of peptide using Thioﬂavin T (ThT) ﬂuorescence measurement
was carried out as previously described [5]. ThT ﬂuorescence
intensity was monitored and the excitation and emission wave-
lengths were 440 and 485 nm, respectively. Sigmoidal curves were
ﬁt to the Gompertz function [5]. Positive fractions were re-chro-
matographed and assayed.
2.4. Sequence determination and database search
A drop of 1 lL of the supernatant was deposited as a spot on a
polished steel target (MTP384 polished steel target, Bruker Dalton-
ics Japan, Yokohama, Japan) and air-dried. Each spot was then cov-
ered with 1 lL of the matrix solution which was prepared on a
daily basis and consisted of a saturated solution of a-cyano-4-
hydroxycinnamic acid (CHCA) (Bruker Daltonics Japan) in 33% ace-
tonitrile and 1% triﬂuoroacetic acid (TFA). Mass-spectra (MS and
MS/MS) were measured using a Ultraﬂex III MALDI TOF/TOF (Bru-
ker Daltonics Japan) in the positive ion mode. Mass spectrometer
was calibrated externally using a peptide calibration standard II
(Bruker Daltonics Japan) in the m/z range 500 to 6000 by spotting
the calibration standard immediately next to the sample spot to
minimize any mass measurement error. De novo generated pep-
tide sequences were used for homology searches using the MS
BLAST (NCBI) algorithm.
2.5. Peptide syntheses
Peptides were prepared by the improved 9-ﬂuorenylmethoxy-
carbonyl solid-phase method as previously described [6]. Analyses
by reversed-phase (RP)-HPLC were carried out on-line using LCMS
(Agilent 1100 ion-trap mass spectrometer, HCT ultra (Bruker Dal-
tonics Japan) with analytical RP-HPLC columns, HiPep-Cadenza
(3.0  150 mm, HiPep Labs.). Preparative puriﬁcation was carried
out using HiPep-Cadenza (20  150 mm, HiPep Labs.) with a LC-
8A System (Shimadzu). Puriﬁed peptides were accessed by the
above LCMS system (Supplementary data).3. Results
Fatty acids of homogenized bovine whole brain were removed
by extraction with organic solvent and the resulting material was
used to construct a peptide-library after enzymatic digestion.
Digestion has been optimized with a two-hour incubation time
using trypsin, chymotrypsin and pepsin; longer incubation times
did not improve the peptide-mapping patterns. Each digest was
chromatographed on a recently developed HPLC column (HiPep-
Intrada) which had been designed to give high resolution suitable
for peptides and proteins with structures such as amyloid Ab or
prion fragments [7]. The chromatogram of the tryptic digests is
shown in Fig. 1. Fractions were collected in 1 min intervals (ﬂow
rate 3 mL/min) and all fractions were submitted for the screening
assay described in the experimental section. Pooled fractions, No.
4 (7–8 min) and No. 12 (15–16 min) showed signiﬁcant conver-
sions in the screening assay. These fractions were re-chromato-
graphed on an analytical column with the same packing material
(Fig. 2) and each fraction was re-assayed. A large number of sam-
ples were assayed and 12 and 24 h ﬂuorescent intensity was com-
pared to ﬁnd the most effective fractions (Supplementary data
Fig. SF1). In the re-chromatogram pooled fraction 4 (3.5–4.0 min)
pooled (designated as TN044) and fraction 5 (8–10 min)
(designated as TN125) exhibited the most signiﬁcant actions,
Table 1
Peptide primary structure from de novo sequencing.
Sample name Sequence Origin from homology [bos taurus]
TN044-656 FGYGGR Myelin basic protein
TN044-728 FFGSDR Myelin basic protein
TN12-1265 GNVLVVVLAR Hemoglobin subunit beta
TN125-1487 ISQIVSSITASL Tubulin alpha-4a chain
TN125-1575 MDVVNQLVAGGQFR Synaptophysin
Fig. 3. Structural conversion assay of the synthetic peptide TN125-1575. Data were
ﬁtted to a Gompertz curve. (A) rbPrP; (B) rbPrP + synthetic TN125-1575 1.66 lM);
(C) rbPrP + synthetic TN125-1575 (3.3 lM); (D) rbPrP + synthetic TN125-1575
(6.6 lM); (E) rbPrP + synthetic TN125-1575 (13.3 lM); (F) rbPrP + synthetic
TN125-1575 (26.6 lM). The experiment was carried out in triplicate.
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analyses and showed 2 and 3 major components, respectively, with
different m/z (in Supplementary Fig. SF2 upper shows TN125 as an
example). Each signal as the precursor ion was further analyzed by
MS/MS (in Supplementary Fig. SF2 lower).
De novo generated peptide sequences were used for homology
searches in the MS BLAST (NCBI) algorithm. Table 1 summarized
the peptide sequence obtained in this study. To conﬁrm their activ-
ities these peptides were synthesized, puriﬁed and used for struc-
tural conversion assay. Only one peptide (TN125-1575, sequence:
‘‘MDVVNQLVAGGQFR’’) showed signiﬁcant effects and a dose-
dependency was established. Fitting to a Gompertz curve (Fig. 3)
indicates signiﬁcant effects were observed starting at a peptide
concentration of 3.3 lM.
Similar screenings were performed for both chymotryptic and
pepsin digests (chromatograms are shown in the Supplementary
Fig. SF3). In the case of chymotrypsin effective components have
been identiﬁed from the fractions. However the peptides could
not be identiﬁed by MALDI-TOF-MS as the fractions contained
numerous compounds and re-chromatography and repeated HPLC
separation caused sample loss. In the case of pepsin no signiﬁcant
fraction was obtained, as the shorter peptides produced using this
enzyme showed no apparent effects.
4. Discussion
Using our structural conversion assay we have discovered a
peptide from natural bovine brain that accelerates the structural
conversion of rbPrP and it originates as a fragment peptide of syn-
aptophysin. Although the exact function of synaptophysin is un-
known, this protein is a 38 KD synaptic vesicle glycoprotein with
four transmembrane domains. The cellular prion protein (PrPC) is
highly expressed at synapses [8] and the relationship between
synaptophysin and prion diseases have been reported [9,10],although the structural conversion by the peptides derived from
synaptophysin has not been described. Prion protein and synapto-
physin are co-localized in the cells [11,12] and interaction between
synaptophysin with PrPC plays a role in synaptic function [10].
These ﬁndings support our present results.
The relationship between dose and effects was clariﬁed with
the synthetic peptide, and indicated that speciﬁc amounts of pep-
tide was necessary to initiate a response (Fig. 3). However at the
stage where screening of the natural library was undertaken the
amounts of target peptides were unknown. Therefore we believe
that more peptides responsible for structural conversion may exist
in the brain and peptides exhibiting opposite effects (that is those
suppressing conversion similar to b-sheet breaker peptides may be
present to maintain homeostasis. Clearly libraries in combination
with top-down sequencing by mass spectrometry can give rapid
and valuable information with small amounts of sample even
when these contain a mixture of components.
This has considerable advantages over the methods used previ-
ously where de novo sequencing could only be performed by Ed-
man degradation. This required time-consuming puriﬁcation of
the samples as sample purity is a prerequisite for sequence eluci-
dation. Today, however, samples containing several components
can be applied as a mixture. The structural elucidation of compo-
nents in active mixtures can then be directly analyzed using high
resolution mass spectrometry. Thus such mixtures give multiple
precursor ions in MALDI-TOF-MS which can be further analyzed
by MS/MS to reveal the sequence of each component (top down
sequencing). All the peptides can then be chemically synthesized
and characterize to ﬁnd the active components. Such an approach
thus minimizes the time required to ﬁnd active components and
allows all components in the mixture to be assessed even when
these are present in only minimal amounts in the original mixture.
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